DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 1)

There are no effective approaches to treatment and prevention of many infectious diseases representing a significant danger to humans. So far, mass vaccine immunization is among the most efficient and widely used approaches to prevent outbreaks of viral and bacterial infections. Mass immunization he...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	L. V. Cherenova, T. V. Kashtigo, Kh. S. Saiadian, M. M. Shmarov
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2017
Materias:	adenoviral vector vaccine clinical trials infectious diseases human adenovirus chimpanzee adenovirus Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/f6dcc476ea964d5290abbcbe7e88105f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f6dcc476ea964d5290abbcbe7e88105f
record_format	dspace
spelling	oai:doaj.org-article:f6dcc476ea964d5290abbcbe7e88105f2021-11-18T08:03:46ZDEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 1)1563-06252313-741X10.15789/1563-0625-2017-2-111-126https://doaj.org/article/f6dcc476ea964d5290abbcbe7e88105f2017-05-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1216https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XThere are no effective approaches to treatment and prevention of many infectious diseases representing a significant danger to humans. So far, mass vaccine immunization is among the most efficient and widely used approaches to prevent outbreaks of viral and bacterial infections. Mass immunization helps to reduce the number of carriers of infections, thus significantly decreasing probability of infection dissemination. Recent promising developments include genetically engineered vaccines based on adenoviral vectors, many of which are already at various stages of clinical trials. Genetic immunization with recombinant adenovirus-based vaccines allows delivery of the genes encoding only required antigens to human cells, thus allowing avoidance of conventional vaccines, e.g., live pathogenic viruses and bacteria, and providing versatile technologies for vaccine development. These advances significantly reduce the time needed for vaccine production and, respectively, the development and creation of new vaccines, thus being an important factor in decreasing risk of epidemics and pandemics. Advantages of adenoviral vectors include high ability of penetration into human cells, a potential for induction of both humoral and cellular immune response, rather long and active production of antigens following administration of adenoviral vectors into the human, safe usage, ease of obtaining preparative quantities of vaccines. In this review, we provide information about the ongoing worldwide clinical trials of adenoviral vector-based vaccines against various infectious diseases, like as to consider selection parameters of volunteers participating in the testing, vaccination schedule, doses and methods of drug administration, results of completed experiments, and preliminary data on currently ongoing research.L. V. CherenovaT. V. KashtigoKh. S. SaiadianM. M. ShmarovSPb RAACIarticleadenoviral vectorvaccineclinical trialsinfectious diseaseshuman adenoviruschimpanzee adenovirusImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 19, Iss 2, Pp 111-126 (2017)
institution	DOAJ
collection	DOAJ
language	RU
topic	adenoviral vector vaccine clinical trials infectious diseases human adenovirus chimpanzee adenovirus Immunologic diseases. Allergy RC581-607
spellingShingle	adenoviral vector vaccine clinical trials infectious diseases human adenovirus chimpanzee adenovirus Immunologic diseases. Allergy RC581-607 L. V. Cherenova T. V. Kashtigo Kh. S. Saiadian M. M. Shmarov DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 1)
description	There are no effective approaches to treatment and prevention of many infectious diseases representing a significant danger to humans. So far, mass vaccine immunization is among the most efficient and widely used approaches to prevent outbreaks of viral and bacterial infections. Mass immunization helps to reduce the number of carriers of infections, thus significantly decreasing probability of infection dissemination. Recent promising developments include genetically engineered vaccines based on adenoviral vectors, many of which are already at various stages of clinical trials. Genetic immunization with recombinant adenovirus-based vaccines allows delivery of the genes encoding only required antigens to human cells, thus allowing avoidance of conventional vaccines, e.g., live pathogenic viruses and bacteria, and providing versatile technologies for vaccine development. These advances significantly reduce the time needed for vaccine production and, respectively, the development and creation of new vaccines, thus being an important factor in decreasing risk of epidemics and pandemics. Advantages of adenoviral vectors include high ability of penetration into human cells, a potential for induction of both humoral and cellular immune response, rather long and active production of antigens following administration of adenoviral vectors into the human, safe usage, ease of obtaining preparative quantities of vaccines. In this review, we provide information about the ongoing worldwide clinical trials of adenoviral vector-based vaccines against various infectious diseases, like as to consider selection parameters of volunteers participating in the testing, vaccination schedule, doses and methods of drug administration, results of completed experiments, and preliminary data on currently ongoing research.
format	article
author	L. V. Cherenova T. V. Kashtigo Kh. S. Saiadian M. M. Shmarov
author_facet	L. V. Cherenova T. V. Kashtigo Kh. S. Saiadian M. M. Shmarov
author_sort	L. V. Cherenova
title	DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 1)
title_short	DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 1)
title_full	DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 1)
title_fullStr	DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 1)
title_full_unstemmed	DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 1)
title_sort	development of vaccines based on adenoviral vectors: a review of foreign clinical studies (part 1)
publisher	SPb RAACI
publishDate	2017
url	https://doaj.org/article/f6dcc476ea964d5290abbcbe7e88105f
work_keys_str_mv	AT lvcherenova developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart1 AT tvkashtigo developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart1 AT khssaiadian developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart1 AT mmshmarov developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart1
_version_	1718422391417208832

DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 1)

Ejemplares similares